XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]          
Primary sources of revenue, description     We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).    
Revenue recognized         $ 2,700
Deferred revenue $ 1,760   $ 1,760   3,532
Revenue | Minimum | Customer Concentration Risk          
Disaggregation Of Revenue [Line Items]          
Concentration risk, percentage 10.00% 26.00% 53.00% 19.00%  
Revenue | Minimum | Customer Concentration Risk | Medicare          
Disaggregation Of Revenue [Line Items]          
Concentration risk, percentage 36.00% 63.00% 14.00% 61.00%  
Up Front Cash Payments          
Disaggregation Of Revenue [Line Items]          
Deferred revenue $ 1,000   $ 1,000    
Other Long-term Liabilities          
Disaggregation Of Revenue [Line Items]          
Non-current deferred revenue $ 1,000   $ 1,000   $ 1,400